National Institutes of Health (NIH)
NEWS
The National Institutes of Health has awarded Fannin Innovation Studio® a $1 million grant to continue development of PM-43I, the company’s anti-asthma drug, in collaboration with portfolio company Atrapos Therapeutics, LLC., as a more effective alternative to steroids.
Motif Bio plc announced that the Company will be utilising NIAID’s1 suite of preclinical services through JMI Laboratories to evaluate iclaprim against Listeria monocytogenes, a Gram-positive bacteria causing food-borne, life-threatening infections.
When a group of our neurons get activated by thinking hard about a math problem or the vibrant colors of an exotic flower, within a single second blood flow to those brain cells increases a bit.
The goal of the research is to develop a treatment that will spur the immune system into producing antibodies capable of disarming numerous strains of HIV.
Investigating Quantitative EEG as Biomarker of Patient Response to Treatment in Future Efficacy Studies
Retrophin, Inc. announced that it has entered into a three-way Cooperative Research and Development Agreement with the National Institutes of Health’s National Center for Advancing Translational Sciences and patient advocacy foundation Alagille Syndrome Alliance to collaborate on research efforts aimed at the identification and development of potentially novel therapeutics for Alagille syndrome.
Here’s a preview of just a handful of opportunities, companies and speakers and what they’re presenting.
Grant funding will support preclinical studies of a newly discovered medication to control asthma without the use of inhalers
The employees were terminated over allegations of industrial espionage on behalf of the Chinese government. MD Anderson ought to quell concerns of racial profiling following the firings.
JOBS
IN THE PRESS